医学
结节病
肺功能测试
强的松
肺动脉高压
内科学
肺纤维化
心脏病学
肺
胃肠病学
作者
John A. Belperio,Faisal M. Shaikh,Fereidoun Abtin,Michael C. Fishbein,S. Weigt,Rajan Saggar,Joseph P. Lynch
出处
期刊:JAMA
[American Medical Association]
日期:2022-03-01
卷期号:327 (9): 856-856
被引量:157
标识
DOI:10.1001/jama.2022.1570
摘要
Sarcoidosis has a mortality rate of approximately 7% within a 5-year follow-up period. More than 10% of patients with pulmonary sarcoidosis develop progressive disease and more than 60% of deaths are due to advanced pulmonary sarcoidosis. Oral glucocorticoids with or without another immunosuppressive agent are the first-line therapy for symptomatic patients with abnormal pulmonary function test results and lung infiltrates. Patients with sarcoidosis and precapillary pulmonary hypertension should be treated with therapies such as phosphodiesterase inhibitors and prostacyclin analogues.
科研通智能强力驱动
Strongly Powered by AbleSci AI